These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10666656)

  • 1. Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues.
    Reiffel JA
    Curr Opin Cardiol; 2000 Jan; 15(1):7-11. PubMed ID: 10666656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia.
    Prystowsky EN
    Clin Cardiol; 1994 Sep; 17(9 Suppl 2):II7-10. PubMed ID: 7882612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoiding drug problems. The safety of drugs for supraventricular tachycardia.
    Reimold SC
    Eur Heart J; 1997 May; 18 Suppl C():C40-4. PubMed ID: 9152674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist.
    Thibault B; Nattel S
    J Cardiovasc Electrophysiol; 1999 Mar; 10(3):472-81. PubMed ID: 10210515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
    Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ
    J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias.
    Simons GR; Eisenstein EL; Shaw LJ; Mark DB; Pritchett EL
    Am J Cardiol; 1997 Dec; 80(12):1551-7. PubMed ID: 9416934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW
    N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death.
    Prystowsky EN
    Am J Cardiol; 1996 Oct; 78(8A):35-41. PubMed ID: 8903274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
    Page RL; Connolly SJ; Wilkinson WE; Marcello SR; Schnell DJ; Pritchett EL;
    Am Heart J; 2002 Apr; 143(4):643-9. PubMed ID: 11923801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic drug initiation in patients with atrial fibrillation.
    Pinski SL; Helguera ME
    Prog Cardiovasc Dis; 1999; 42(1):75-90. PubMed ID: 10505494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risks and side effects in treatment of supraventricular tachycardia].
    Lüderitz B
    Z Gesamte Inn Med; 1993 Sep; 48(9):459-65. PubMed ID: 8212752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
    Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
    Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current treatment of supraventricular tachycardia: drug therapy].
    Manz M; Lüderitz B
    Z Gesamte Inn Med; 1993 Sep; 48(9):430-8. PubMed ID: 8212748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antiarrhythmic drug in pediatric use: sotalol.
    Pfammatter JP; Paul T
    Pediatr Cardiol; 1997; 18(1):28-34. PubMed ID: 8960489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.